Biologic Therapies May Reduce the Risk of COVID-19 in Patients With Inflammatory Bowel Disease

Bezzio, Cristina; Pellegrini, Lucienne; Manes, Gianpiero; Arena, Ilaria; Picascia, Desirée; Corte, C. Della; Devani, Massimo; Schettino, M.; Saibeni, Simone

doi:10.1093/ibd/izaa242

Cited by 16 publications

(22 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A single-center study, conducted on 522 IBD patients (both adult and pediatric subjects) living in an urban area with a high prevalence of COVID-19 infection, found no infected subjects either among those receiving immunosuppressant drugs (no.=22%) or biologics (no.=16%), or among those not treated with this class of compounds [10] . A multicenter study carried out by the Italian Group for Inflammatory Bowel Disease (IG-IBD) collected 79 cases of IBD patients with the SARS-CoV-2 infection, ensuing in death in 6 patients [11] . No IBD-specific features resulted associated with a poor outcome (pneumonia, need for respiratory therapies, hospitalization, and death), whereas older age, male sex, and presence of co-morbidities were all significant predictors of a worse outcome [11] .…”

Section: Introductionmentioning

confidence: 99%

“…A multicenter study carried out by the Italian Group for Inflammatory Bowel Disease (IG-IBD) collected 79 cases of IBD patients with the SARS-CoV-2 infection, ensuing in death in 6 patients [11] . No IBD-specific features resulted associated with a poor outcome (pneumonia, need for respiratory therapies, hospitalization, and death), whereas older age, male sex, and presence of co-morbidities were all significant predictors of a worse outcome [11] .…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Impact of the COVID-19 outbreak and the serum prevalence of SARS-CoV-2 antibodies in patients with inflammatory bowel disease treated with biologic drugs

Bossa

Carparelli

Palmieri

et al. 2021

Digestive and Liver Disease

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Impact of the COVID-19 outbreak and the serum prevalence of SARS-CoV-2 antibodies in patients with inflammatory bowel disease treated with biologic drugs

Bossa

Carparelli

Palmieri

et al. 2021

Digestive and Liver Disease

View full text Add to dashboard Cite

“…A growing body of evidence demonstrates that in IBD patients the use of systemic immunosuppression is not associated with an increased risk of COVID-19 patients with IBD[ 96 - 100 ]. Furthermore, we must also keep in mind that the main objective of pharmacological treatments in IBD is to reduce inflammation levels.…”

Section: Rage Axis Activation and Ras Imbalance In Ibd Patients Infected With Sars-cov-2mentioning

confidence: 99%

“…In this sense, in addition to interfering with signaling pathways, many drugs used in the current treatments also decrease the expression of RAGE and the bioavailability of some RAGE ligands, particularly the alarmins HMGB1 and S100 protein family members[ 96 , 97 ]. Indeed, several authors remark the possible protective role of IBD therapy against SARS-CoV-2 infection, especially through interfering with cytokine activity observed in the clinical course of COVID-19[ 98 - 100 ].…”

Section: Rage Axis Activation and Ras Imbalance In Ibd Patients Infected With Sars-cov-2mentioning

confidence: 99%

Receptor for advanced glycation end-products axis and coronavirus disease 2019 in inflammatory bowel diseases: A dangerous liaison?

Rojas

Schneider

Lindner

et al. 2021

WJG

View full text Add to dashboard Cite

Compelling evidence supports the crucial role of the receptor for advanced glycation end-products (RAGE) axis activation in many clinical entities. Since the beginning of the coronavirus disease 2019 pandemic, there is an increasing concern about the risk and handling of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in inflammatory gastrointestinal disorders, such as inflammatory bowel diseases (IBD). However, clinical data raised during pandemic suggests that IBD patients do not have an increased risk of contracting SARS-CoV-2 infection or develop a more severe course of infection. In the present review, we intend to highlight how two potentially important contributors to the inflammatory response to SARS-CoV-2 infection in IBD patients, the RAGE axis activation as well as the cross-talk with the renin-angiotensin system, are dampened by the high expression of soluble forms of both RAGE and the angiotensin-converting enzyme (ACE) 2. The soluble form of RAGE functions as a decoy for its ligands, and soluble ACE2 seems to be an additionally attenuating contributor to RAGE axis activation, particularly by avoiding the transactivation of the RAGE axis that can be produced by the virus-mediated imbalance of the ACE/angiotensin II/angiotensin II receptor type 1 pathway.

show abstract

“…Data on SARS-CoV-2 infection and outcomes in individuals with immune defects, including those with primary immunodeficiency due to genetic causes or secondary immunosuppression related to immunomodulatory therapies, remain limited. While there is concern that immunomodulatory treatments may negatively affect the clinical outcome, in some cases, selected biologics may protect against a virally provoked cytokine storm associated with severe forms of COVID-19 ( 2 , 3 ).…”

Section: Introductionmentioning

confidence: 99%

COVID-19 prevalence and outcomes in patients receiving biologic therapies at an infusion center in New York City

Harada

Cunningham‐Rundles

2021

Clinical Immunology

View full text Add to dashboard Cite

To better understand COVID-19 infection in patients receiving biologic and immunomodulatory therapies, we evaluated prevalence and outcomes for symptomatic cases of COVID-19 at a large therapeutic infusion center in New York City during the height of the pandemic. 2074 patients received treatment with biologic infusions at our center between March and May 2020, and 34 patients developed symptomatic COVID-19 infection, for an overall low rate of 1.64%. The majority of infections and deaths were in a small subset of patients with a primary immunodeficiency. Patients with inflammatory or autoimmune conditions requiring biologic therapies tended to have mild cases. Higher inflammatory responses were observed in patients who died.

show abstract

Biologic Therapies May Reduce the Risk of COVID-19 in Patients With Inflammatory Bowel Disease

Cited by 16 publications

References 5 publications

Impact of the COVID-19 outbreak and the serum prevalence of SARS-CoV-2 antibodies in patients with inflammatory bowel disease treated with biologic drugs

Impact of the COVID-19 outbreak and the serum prevalence of SARS-CoV-2 antibodies in patients with inflammatory bowel disease treated with biologic drugs

Receptor for advanced glycation end-products axis and coronavirus disease 2019 in inflammatory bowel diseases: A dangerous liaison?

COVID-19 prevalence and outcomes in patients receiving biologic therapies at an infusion center in New York City

Contact Info

Product

Resources

About